The DOI matches its Crossref record; 109 of the 110 references it cites were found in a registry or an index.
CAR-T cell therapy: current limitations and potential strategies
Open accessAbstract
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certain subsets of B cell leukemia or lymphoma, many challenges limit the therapeutic efficacy of CAR-T cells in solid tumors and hematological malignancies. Barriers to effective CAR-T cell therapy include severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration. In addition, the host and tumor microenvironment interactions with CAR-T cells critically alter CAR-T cell function. Furthermore, a complex workforce is required to develop and implement these treatments. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells with improved anti-tumor activity and decreased toxicity are necessary. In this review, we discuss recent innovations in CAR-T cell engineering to improve clinical efficacy in both hematological malignancy and solid tumors and strategies to overcome limitations of CAR-T cell therapy in both hematological malignancy and solid tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To address this, various immunotherapeutic strategies have emerged, including adoptive cell transfer, primarily utilizing genetically modified T cells expressing chimeric antigen receptors (CAR T-cells) to recognize and eliminate cancer cells directly (Sterner and Sterner, 2021). Adjuvant therapies, such as dendritic cell, mRNA, and peptide-based vaccinations, aim to boost the patient’s anticancer”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Despite their general tolerability, immune checkpoint inhibitors (ICIs) may induce cytokine storms in patients, and T cell-engaging bispecific antibodies and TCR/CAR-T engineered T cells, contingent on the target, could result in significant off-target tissue destruction, leading to associated morbidity and mortality (Sterner and Sterner, 2021; Johnson et al., 2022).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Sterner and Sterner, 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Research works printed but not linked: 1
- Peter P. Lee (eds.) Tumor Microenvironment (Springer) https://www.springer.com/gp/book/9783030388614
Cited by
Sorted by citations
Items 401–500 of 1,002
Fang, L., Yuan, S., Wang, M., Zhang, C., Wang, X., Li, H., Yang, J., Li, W., Sun, N., Zhang, Q., et al. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01626-4 · Cited by 34
Unlocking the potential of Tregs: innovations in CAR technology
Cier, C. J. R., Valentini, N., & Lamarche, C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1267762 · Cited by 33
Expanding CAR-T cell immunotherapy horizons through microfluidics
Kim, H., Kim, S., Lim, H., & Chung, A. J. (2024) · Lab on a Chip · doi:10.1039/d3lc00622k · Cited by 34
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Mei, J., Liu, X., Tian, H., Chen, Y., Cao, Y., Zeng, J., Liu, Y., Chen, Y., Gao, Y., Yin, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1656 · Cited by 34
PET/CT in the Evaluation of CAR-T Cell Immunotherapy in Hematological Malignancies
Singh, S. B., Bhandari, S., Siwakoti, S., Kumar, M., Singh, R., Bhusal, S., Sharma, K., Bhandari, S., & Khanal, K. (2024) · Molecular Imaging · doi:10.1177/15353508241257924 · Cited by 34
Κωστόπουλος, Ν., Costabile, F., Krimitza, E., Beghi, S., Goia, D., Perales-Linares, R. F., Thyphronitis, G., Lariviere, M. J., Chong, E. A., Schuster, S. J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012599 · Cited by 34
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 34
Yang, Y., Peng, H., Wang, J., & Li, F. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00573-9 · Cited by 37
Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
Shahid, S., Prockop, S. E., Flynn, G. C., Mauguen, A., White, C., Bieler, J., McAvoy, D. P., Hosszu, K., Cancio, M., Jakubowski, A. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015157 · Cited by 34
Yuan, H., Xu, R., Li, S., Zheng, M., Tong, Q., Xiang, M., & Zhang, Y. (2025) · MedComm · doi:10.1002/mco2.70121 · Cited by 36
T cells in cancer: mechanistic insights and therapeutic advances
Pu, J., Liu, T., Zhou, Y., Chen, M., Fu, X., Wan, Y., Wang, J., Chen, B., Sharma, A., Lukacs‐Kornek, V., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00807-w · Cited by 33
Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells
Meléndez, A. V., Cárdenas, R. M.-H. V., Lagies, S., Strietz, J., Šiukštaitė, L., Thomas, O. S., Tomisch, J., Weber, W., Kammerer, B., Römer, W., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04524-7 · Cited by 34
Immunotherapy approaches for hematological cancers
Lanier, O. L., Pérez‐Herrero, E., Andrea, A. P. D. ’., Bahrami, K., Lee, E. Y. P., Ward, D. M., Ayala-Suárez, N., Rodríguez-Méndez, S. M., & Peppas, N. A. (2022) · iScience · doi:10.1016/j.isci.2022.105326 · Cited by 36
Drougkas, K., Karampinos, K. I., Karavolias, I., Koumprentziotis, I., Ploumaki, I., Triantafyllou, E., Trontzas, I. P., & Kotteas, E. A. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04547-4 · Cited by 30
Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities
Cassar, E., Kartikasari, A. E. R., & Plebanski, M. (2022) · Cancers · doi:10.3390/cancers14225488 · Cited by 31
Application of injectable hydrogels in cancer immunotherapy
Liu, C., Liao, Y., Liu, L., Xie, L., Liu, J., Zhang, Y., & Li, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1121887 · Cited by 33
Mody, H. R., Ogasawara, K., Zhu, X., Miles, D., Shastri, P. N., Gokemeijer, J., Liao, M. Z., Kasichayanula, S., Yang, T., Chemuturi, N. V., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2986 · Cited by 34
Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology
Menéndez, J. A., Cuyàs, E., Encinar, J. A., Steen, T. V., Verdura, S., Llop‐Hernández, À., López, J., Serrano‐Hervás, E., Osuna, S., Martín-Castillo, B., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13582 · Cited by 41
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy
Yuan, M., Wang, W., Hawes, I., Han, J., Yao, Z., & Bertaina, A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360237 · Cited by 33
IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: From bench to bedside
Vahidi, S., Touchaei, A. Z., & Samadani, A. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112156 · Cited by 31
Diffuse Gastric Cancer: A Comprehensive Review of Molecular Features and Emerging Therapeutics
Wu, L. W., Jang, S. J., Shapiro, C., Fazlollahi, L., Wang, T. C., Ryeom, S. W., & Moy, R. H. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01097-2 · Cited by 37
Chen, Z., Shu, J., Hu, Y., & Mei, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.019 · Cited by 32
Jurczak, M., & Druszczyńska, M. (2025) · Pathogens · doi:10.3390/pathogens14020196 · Cited by 36
Nanoparticles Targeting Innate Immune Cells in Tumor Microenvironment
Jang, H., Kim, E. H., Chi, S.-G., Kim, S. H., & Yang, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810009 · Cited by 33
Genome editing via non-viral delivery platforms: current progress in personalized cancer therapy
Lan, T., Que, H., Luo, M., Zhao, X., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01550-8 · Cited by 31
Worked to the bone: antibody-based conditioning as the future of transplant biology
Griffin, J. M., Healy, F. M., Dahal, L. N., Fløisand, Y., & Woolley, J. F. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01284-6 · Cited by 31
Incidence of MACE in Patients Treated With CAR-T Cell Therapy
Lefebvre, B., Kang, Y., Vakilpour, A., Onoue, T., Frey, N. V., Brahmbhatt, P., Huang, B. Z., Oladuja, K., Koropeckyj-Cox, D., Wiredu, C., et al. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.07.009 · Cited by 29
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review)
Yang, S., Zou, R.-Q., Dai, Y.-S., Hu, Y.-F., Li, F., & Hu, H. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5585 · Cited by 30
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?
Aggeletopoulou, I., Kalafateli, M., & Triantos, C. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052631 · Cited by 31
Mog, B. J., Marcou, N., DiNapoli, S. R., Pearlman, A. H., Nichakawade, T. D., Hwang, M. S., Douglass, J., Hsiue, E. H.-C., Glavaris, S. A., Wright, K. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7123 · Cited by 31
Chemokines in the tumor microenvironment: implications for lung cancer and immunotherapy
Jung, H., & Paust, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1443366 · Cited by 31
Malik, S., Sureka, N., Ahuja, S., Aden, D., Zaheer, S., & Zaheer, S. (2024) · Cell Biology International · doi:10.1002/cbin.12226 · Cited by 32
CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside
Zhu, X., Xue, J., Jiang, H., & Xue, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02151-3 · Cited by 31
Generation of tumor neoantigens by RNA splicing perturbation
Rosenberg-Mogilevsky, A., Siegfried, Z., & Karni, R. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.10.008 · Cited by 30
Song, J., Zhu, J. W., Jiang, Y., Guo, Y., Liu, S., Qiao, Y., Du, Y., & Li, J. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189277 · Cited by 31
Wang, Z., & Kelley, S. O. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01315-2 · Cited by 33
Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies
Huang, M., Zhang, Y., Chen, Z., Yu, X., Luo, S., Peng, X., & Li, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107726 · Cited by 31
Hosking, M. P., Shirinbak, S., Omilusik, K., Chandra, S., Kaneko, M., Gentile, A., Yamamoto, S., Shrestha, B., Grant, J., Boyett, M., et al. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.05.007 · Cited by 30
A tumor-on-a-chip for in vitro study of CAR-T cell immunotherapy in solid tumors
Liu, H., Noguera-Ortega, E., Dong, X., Lee, W. D., Chang, J., Aday, S., Li, Y., Shin, Y., Shi, X., Liousia, M., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02845-z · Cited by 41
Mateus-Tique, J., Lakshmi, A., Singh, B., Iyer, R., Sánchez-Paulete, A. R., Falcomatà, C., Lin, M. J., Pantsulaia, G., Tepper, A., Nguyen, T., et al. (2026) · Cancer Cell · doi:10.1016/j.ccell.2025.12.021 · Cited by 30
Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology
Nezhad, M. S., Yazdanifar, M., Abdollahpour‐Alitappeh, M., Sattari, A., Seifalian, A. M., & Bagheri, N. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27882 · Cited by 30
Intratumoral microbiota: new frontiers in tumor immunity
Zhang, Z., Liao, Y., & Tang, D. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac063 · Cited by 30
Stock, S., Benmebarek, M.-R., Kluever, A.-K., Darowski, D., Jöst, C., Stubenrauch, K., Benz, J., Freimoser–Grundschober, A., Moessner, E., Umaña, P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005054 · Cited by 35
Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors
Nie, D., Guo, T., Yue, M., Li, W., Zong, X., Zhu, Y., Huang, J., & Lin, M. (2022) · Biomolecules · doi:10.3390/biom12091239 · Cited by 33
CARs: a new approach for the treatment of autoimmune diseases
Sun, Y., Yuan, Y., Zhang, B., & Zhang, X. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2212-5 · Cited by 31
Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance
Qin, Y., & Xu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053120 · Cited by 32
T cell-responsive macroporous hydrogels for in situ T cell expansion and enhanced antitumor efficacy
Bhatta, R., Han, J., Liu, Y., Yang, B., & Wang, H. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121972 · Cited by 30
Naeem, M., Hazafa, A., Bano, N., Ali, R., Farooq, M., Razak, S. I. A., Lee, T. Y., & Devaraj, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121409 · Cited by 32
Cheng, K., Feng, X., Chai, Z., Wang, Z., Liu, Z., Yan, Z., Wang, Y., & Zhang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044197 · Cited by 29
Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases
Felten, R., Mertz, P., Sebbag, E., Scherlinger, M., & Arnaud, L. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103612 · Cited by 31
Li, Y.-R., Ochoa, C. J., Zhu, Y., Kramer, A. B., Wilson, M., Fang, Y., Chen, Y., Singh, T., DiBernardo, G., Zhu, E., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107952 · Cited by 31
Functional CRISPR screens in T cells reveal new opportunities for cancer immunotherapies
Xiang, M., Li, H., Zhan, Y., Ma, D., Gao, Q., & Fang, Y. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01987-z · Cited by 29
Regulatory T cell-based therapy in type 1 diabetes: Latest breakthroughs and evidence
Huang, Q., & Zhu, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112724 · Cited by 33
Strategies for Improving CAR T Cell Persistence in Solid Tumors
Wittling, M. C., Cole, A. C., Brammer, B., Diatikar, K. G., Schmitt, N. C., & Paulos, C. M. (2024) · Cancers · doi:10.3390/cancers16162858 · Cited by 31
Li, Y.-R., Zhou, K., Lee, D., Zhu, Y., Halladay, T., Yu, J., Zhou, Y., Lyu, Z., Fang, Y., Chen, Y., et al. (2025) · Nature Protocols · doi:10.1038/s41596-024-01077-w · Cited by 30
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer
Cai, J., Liu, Z., Chen, S., Zhang, J., Li, H., Wang, X., Feng, Y., Wang, S., Li, X., Li, Y., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00625-8 · Cited by 36
CAR T-cell therapy in SLE: A systematic review
Nordmann-Gomes, A., Khalili, L., Tang, W., Geraldino-Pardilla, L. B., Gartshteyn, Y., Clancy, R., Souvignier, M., Suh, S., Sadelain, M., & Askanase, A. (2025) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2025.152786 · Cited by 29
Yashaswini, C. N., Cogliati, B., Qin, T., To, T., Williamson, T., Papp, T. E., Li, K., Rasul, R. B., Chen, L., Lightstone, A., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx0368 · Cited by 47
Localized delivery of immunotherapeutics: A rising trend in the field
Wang, J., Zhang, Y., Pi, J., Xing, D., & Wang, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.013 · Cited by 31
Better by design: What to expect from novel CAR-engineered cell therapies?
Luginbuehl, V., Abraham, E., Kovar, K., Flaaten, R., & Müller, A. M. S. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.107917 · Cited by 29
Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review
Fang, Z., Ding, Y., Xue, Z., Li, P., Li, J., & Li, F. (2022) · Discover Oncology · doi:10.1007/s12672-022-00539-5 · Cited by 29
Camilli, M., Maggio, L., Tinti, L., Lamendola, P., Lanza, G. A., Crea, F., & Lombardo, A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1090103 · Cited by 29
Enabling CAR T ‐cell therapies for HIV ‐positive lymphoma patients – A call for action
Hattenhauer, T., Mispelbaum, R., Hentrich, M., Boesecke, C., & Monin, M. B. (2023) · HIV Medicine · doi:10.1111/hiv.13514 · Cited by 29
Drug delivery methods for cancer immunotherapy
Pérez‐Herrero, E., Lanier, O. L., Krishnan, N., D’Andrea, A., & Peppas, N. A. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01405-9 · Cited by 29
Liang, R., Wu, C., Liu, S., & Zhao, W. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2075986 · Cited by 29
Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer
Hu, C., Liu, M., Li, Y., Zhao, Y., Sharma, A., Liu, H., & Schmidt‐Wolf, I. G. H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213716 · Cited by 30
Nanomaterials Boost CAR‐T Therapy for Solid Tumors
Long, J., Wang, Y., Jiang, X., Ge, J., Chen, M., Zheng, B., Wang, R., Wang, M., Xu, M., Qi, K., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304615 · Cited by 28
Zhang, P.-F., & Xie, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1362133 · Cited by 29
Court, A. C., Parra-Crisóstomo, E., Castro-Córdova, P., Abdo, L. D. M., Aragão, E. A. A., Lorca, R., Figueroa, F. E., Bonamino, M., & Khoury, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05627-4 · Cited by 28
Miao, H., Yuan, F., Pan, C.-X., Yang, H., Wang, Z., Qi, Y., Wu, Y. Z., Zhang, Y., Liu, F., Huang, H., et al. (2025) · Medicine Plus · doi:10.1016/j.medp.2025.100087 · Cited by 33
Organoids as models of immune-organ interaction
Harter, M. F., Recaldin, T., & Gjorevski, N. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116214 · Cited by 31
CAR-engineered cell therapies: current understandings and future perspectives
Bayat, M., & Nahand, J. S. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00401-4 · Cited by 33
Nanoparticle-based immunotherapy of pancreatic cancer
Nzeteu, G. A. N., Gibbs, B. F., Kotnik, N., Troja, A., Bockhorn, M., & Meyer, N. H. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.948898 · Cited by 28
Chen, Y., Chen, Y., Tan, S., Zheng, Y., Liu, S., Zheng, T., Mi, Y., Lin, S., Yang, C., & Li, W. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2186684 · Cited by 28
Eras of designer Tregs: Harnessing synthetic biology for immune suppression
Tuomela, K., Salim, K., & Levings, M. K. (2023) · Immunological Reviews · doi:10.1111/imr.13254 · Cited by 30
Eisenhut, P., Marx, N., Borsi, G., Papež, M., Ruggeri, C., Baumann, M., & Borth, N. (2023) · New Biotechnology · doi:10.1016/j.nbt.2023.11.003 · Cited by 33
Optogenetic technologies in translational cancer research
Malogolovkin, A. S., Egorov, A. D., Karabelsky, A. V., Ivanov, R. A., & Verkhusha, V. V. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.108005 · Cited by 27
The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy
Ganjoo, S., Gupta, P., Corbali, H. I., Nanez, S., Riad, T. S., Duong, L. K., Barsoumian, H. B., Masrorpour, F., Jiang, H., Welsh, J. W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1172931 · Cited by 32
Yue, B., Gao, Y., Hu, Y., Zhan, M., Wu, Y., & Lu, L. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1731 · Cited by 26
EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma
Sterner, R. C., & Sterner, R. M. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1434495 · Cited by 27
Self-citationEmerging advances in drug delivery systems (DDSs) for optimizing cancer complications
Li, K., Guo, B., Gu, J., Ta, N., Gu, J., Yu, H., Sun, M., & Han, T. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101375 · Cited by 30
PROTAC delivery in tumor immunotherapy: Where are we and where are we going?
Li, Y., Wu, Y., Gao, S., Sun, T., & Jiang, C. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.076 · Cited by 29
Lawton, M. L., Inge, M. M., Blum, B. C., Smith-Mahoney, E. L., Bolzan, D., Lin, W., McConney, C., Porter, J., Moore, J., Youssef, A., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002943 · Cited by 25
Skaličková, M., Vanova, K. H., Uher, O., Fialová, J. L., Petrláková, K., Masařík, M., Kejík, Z., Pavel Martasek, E., Pacák, K., & Jakubek, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479483 · Cited by 28
Guo, Y., Wang, H., Liu, S., Zhang, X., Zhu, X., Huang, L., Zhong, W., Guan, L., Chen, Y., Xiao, M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adp9009 · Cited by 27
Amoozgar, B., Bangolo, A., Mansour, C., Eliáš, D., Mohamed, A., Thor, D. C., Ehsanullah, S. U. M., Tran, H. H.-V., Aguilar, I. K., & Weissman, S. I. (2025) · Cancers · doi:10.3390/cancers17142397 · Cited by 30
Crosstalk between cGAS-STING pathway and autophagy in cancer immunity
Lu, Q., Chen, Y., Li, J., Zhu, F., & Zheng, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139595 · Cited by 28
Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials
Özer, M., Goksu, S. Y., Akagündüz, B., George, A., & Şahin, İ. (2023) · Cancers · doi:10.3390/cancers15061808 · Cited by 27
Biomaterials for chimeric antigen receptor T cell engineering
Niu, H., Zhao, P., & Sun, W. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.04.043 · Cited by 28
Loureiro, L. R., Hoffmann, L., Neuber, C., Rupp, L., Arndt, C., Kegler, A., Kubeil, M., Hagemeyer, C. E., Stephan, H., Schmitz, M., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02912-w · Cited by 27
Diverse drug delivery systems for the enhancement of cancer immunotherapy: an overview
Liu, X., Cheng, Y., Mu, Y., Zhang, Z., Tian, D., Liu, Y., Hu, X., & Wen, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1328145 · Cited by 29
Tran, T. M., Thakuri, B. K. C., Nurmukhambetova, S. T., Lee, J., Hu, P., Tran, N. Q., Steimle, B. L., Dash, P., & Schneider, D. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008261 · Cited by 28
Enhanced and sustained T cell activation in response to fluid shear stress
Sarna, N. S., Desai, S. H., Kaufman, B. G., Curry, N. M., Hanna, A. M., & King, M. R. (2024) · iScience · doi:10.1016/j.isci.2024.109999 · Cited by 26
Phage Display as a Medium for Target Therapy Based Drug Discovery, Review and Update
Jahandar-Lashaki, S., Farajnia, S., Faraji-Barhagh, A., Hosseini, Z., Bakhtiyari, N., & Rahbarnia, L. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01195-6 · Cited by 28
Dissolving microneedles for transdermal drug delivery in cancer immunotherapy
Xiang, M., Yang, C., Zhang, L., Wang, S., Ya, R., & Gou, M. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00659c · Cited by 27
Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas
D’Alò, F., Bellesi, S., Maiolo, E., Alma, E., Bellisario, F., Malafronte, R., Viscovo, M., Campana, F., & Hohaus, S. (2024) · Cancers · doi:10.3390/cancers16122243 · Cited by 26
Liao, W., Chen, Y., Shan, S., Chen, Z., Wen, Y., Chen, W., & Zhao, C. (2024) · Phytotherapy Research · doi:10.1002/ptr.8240 · Cited by 26
Advances in manufacturing chimeric antigen receptor immune cell therapies
Ramamurthy, A., Tommasi, A. M., & Saha, K. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01019-4 · Cited by 27
Chang, Y., Chang, M., Bao, X., & Dong, C. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.08.046 · Cited by 28
Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy
Carcopino, C., Erdogan, E., Henrich, M., & Kobold, S. (2024) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2024.100739 · Cited by 27
Metadata
- Authors
- Sterner, R. C., & Sterner, R. M.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Sterner, Rosalie M.
- Venue
- Blood Cancer Journal
- Published
- 2021-04-06
- Volume
- 11
- Issue
- 4
- Pages
- 69-69
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC8024391
- OpenAlex
- W3148729173
- Cited by
- 2,926
- References
- 110
- Citations by year
- 2026: 530 · 2025: 806 · 2024: 726 · 2023: 532 · 2022: 287 · 2021: 42
- FWCI
- 48.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Wisconsin-Madison (T32-GM008692)
- Regenerative Medicine Minnesota (RMM 012819 EPC 003)
- National Institute of General Medical Sciences (T32GM008692)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- CAR T-cell therapy, chimeric antigen receptor, solid tumors, hematologic malignancies, CAR-T cell engineering, tumor microenvironment, antigen escape, CAR-T toxicity, tumor infiltration
- MeSH terms
- Receptors, Chimeric Antigen, Animals, Humans, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Hematologic Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
